On the other hand, the significant favorable effect of escitalopram on TLR-4 and IL-1β comes in consonance with a recently reported study that postulated that treatment with escitalopram selectively inhibits endosomal TLR signaling and suppresses inflammatory cytokine production in human and murine models of RA, which provides a potential mechanism for its anti-inflammatory action [26]. This evidence concerns the gene TLR4 and rheumatoid arthritis.